Quick Answer
Cullinan Therapeutics, Inc. reported Total Revenue of $0.00 for fiscal year 2022.
Cullinan Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | $0.00 -100.0% |
$18.94M | $0.00 |
| Revenue (ASC 606) | — | — | — | $0.00 -100.0% |
$18.94M | $0.00 |
| Net Income | -$219.88M -31.4% |
-$167.38M -9.3% |
-$153.16M -237.7% |
$111.21M +269.6% |
-$65.57M -26.6% |
-$51.80M |
| Diluted EPS | — | — | -$3.69 -255.0% |
$2.38 +256.6% |
-$1.52 | — |
| Total Assets | $448.37M -27.9% |
$621.82M +28.4% |
$484.18M -13.7% |
$561.12M +28.3% |
$437.19M +103.6% |
$214.71M |
| Cash and Equivalents | $88.33M +6.4% |
$83.00M -15.7% |
$98.43M -37.0% |
$156.15M +161.2% |
$59.77M -64.5% |
$168.20M |
| Stockholders Equity | $408.73M -30.8% |
$590.33M +30.1% |
$453.70M -15.2% |
$535.03M +25.9% |
$424.97M +113.5% |
$199.01M +105.2% |
| R&D Expense | $187.40M +31.1% |
$142.90M -3.5% |
$148.16M +61.1% |
$91.95M +59.2% |
$57.75M +33.6% |
$43.21M |
| Operating Income | -$241.65M -22.7% |
-$196.92M -3.1% |
-$191.09M -232.1% |
$144.65M +312.9% |
-$67.95M -12.6% |
-$60.34M |
| Shares Outstanding | 60.24M +3.0% |
58.51M +36.4% |
42.90M -6.3% |
45.80M +3.4% |
44.29M +48.5% |
29.83M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2022 | $0.00 | — | — |
| Revenue (ASC 606) | September 30, 2022 | $0.00 | — | — |
| Net Income | September 30, 2025 | -$50.61M | -24.8% | +27.8% |
| Diluted EPS | September 30, 2024 | -$0.69 | +24.2% | +8.0% |
| Total Assets | September 30, 2025 | $484.13M | -25.9% | -7.0% |
| Cash and Equivalents | September 30, 2025 | $103.33M | +1.2% | +41.9% |
| Stockholders Equity | September 30, 2025 | $451.37M | -28.1% | -8.3% |
| R&D Expense | September 30, 2025 | $41.97M | +18.2% | -31.2% |
| Operating Income | September 30, 2025 | -$55.59M | -13.8% | +26.7% |
| Shares Outstanding | September 30, 2025 | 59.08M | +1.6% | +0.0% |
- Cullinan Therapeutics, Inc. reported Total Revenue of $0.00 for fiscal year 2022.
- Cullinan Therapeutics, Inc. showed a decrease of -100.0% in Total Revenue compared to the prior fiscal year.
- Cullinan Therapeutics, Inc. reported Revenue (ASC 606) of $0.00 for fiscal year 2022.
- Cullinan Therapeutics, Inc. showed a decrease of -100.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Cullinan Therapeutics, Inc. reported Net Income of -$219.88 million for fiscal year 2025.
- Cullinan Therapeutics, Inc. showed a decrease of -31.4% in Net Income compared to the prior fiscal year.
- Cullinan Therapeutics, Inc. reported Diluted EPS of $3.69 per share (loss) for fiscal year 2023.
- Cullinan Therapeutics, Inc. showed a decrease of -255.0% in Diluted EPS compared to the prior fiscal year.
- Cullinan Therapeutics, Inc. reported Total Assets of $448.37 million for fiscal year 2025.
- Cullinan Therapeutics, Inc. showed a decrease of -27.9% in Total Assets compared to the prior fiscal year.
- Cullinan Therapeutics, Inc. reported Cash and Equivalents of $88.33 million for fiscal year 2025.
- Cullinan Therapeutics, Inc. showed an increase of +6.4% in Cash and Equivalents compared to the prior fiscal year.
- Cullinan Therapeutics, Inc. reported Stockholders Equity of $408.73 million for fiscal year 2025.
- Cullinan Therapeutics, Inc. showed a decrease of -30.8% in Stockholders Equity compared to the prior fiscal year.
- Cullinan Therapeutics, Inc. reported R&D Expense of $187.40 million for fiscal year 2025.
- Cullinan Therapeutics, Inc. showed an increase of +31.1% in R&D Expense compared to the prior fiscal year.
- Cullinan Therapeutics, Inc. reported Operating Income of -$241.65 million for fiscal year 2025.
- Cullinan Therapeutics, Inc. showed a decrease of -22.7% in Operating Income compared to the prior fiscal year.
- Cullinan Therapeutics, Inc. reported Shares Outstanding of 60.24 million shares for fiscal year 2025.
- Cullinan Therapeutics, Inc. showed an increase of +3.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: